Kymriah contains the active ingredient Tisagenlecleucel, which belongs to the group of drugs used to treat acute lymphoblastic leukemia and non-Hodgkin lymphoma. The drug is prepared in the form of a solution for injection and is indicated for the treatment of acute lymphoblastic leukemia. However, in the course of drug treatment can cause some unwanted side effects such as, so before using Kymriah, patients need to learn carefully and follow the doctor's instructions.